Skip to main content

Recombinant Lactococcus Lactis Expressing M1-HA2 Fusion Protein Provides Protective Mucosal Immunity Against H9N2 Avian Influenza Virus in Chickens.

H9N2 subtype avian influenza virus of low pathogenicity (LPAIV) are distributed worldwide and cause enormous economic losses in the poultry industry. Although almost all the chickens immunized with the inactivated vaccine, the disease is still widespread. We speculate that increase mucosal or cellular immune response may contribute to improving the H9N2 virus surveillance. 

In this study, we Bovine Recombinant Proteins constructed a novel Lactococcus lactis (L. lactis) strain expressing a recombinant fusion protein consisting of the M1 and HA2 proteins derived from the H9N2 viral strain endemic conserved antigens. M1-HA2 fusion protein was cloned downstream of the gene encoding the secretory peptide, and we subsequently confirmed that the fusion protein is secreted from L. 

lactis by Western blotting. We assess the immunogenicity and protective effects of recombinant L. lactis this tension. Eight chicken 1-day-old were divided into four groups, and the experimental group orally vaccinated twice with recombinant L. lactis strain. fecal and intestinal samples, sera and bronchoalveolar lavage fluid was collected at 7, 14 and 21 days post-vaccination (DPV). 

Chickens vaccinated with a recombinant L. lactis strains showed significantly increase the levels of serum antibodies, T cell-mediated immune responses, and mucosal secretory IgA (SIgA). Following challenge with H9N2 virus in 21 DPV, chickens vaccinated with the recombinant L. lactis strains showed weight loss, lowering viral titers in the lungs, and reduce the pathological damage lungs.
Recombinant Lactococcus Lactis Expressing M1-HA2 Fusion Protein Provides Protective Mucosal Immunity Against H9N2 Avian Influenza Virus in Chickens.


 In summary, our results suggest that Cat Recombinant Proteins recombinant L. lactis strain H9N2 M1-HA2 express the fusion protein can induce a protective mucosal and systemic immunity. The oral vaccine is the H9N2 virus-specific and is a significant design improvement compared with previous studies. Our study provides a theoretical basis for improving mucosal immune responses to prevent and control the H9N2 virus infection.
Labels:

Comments

Post a Comment

Popular posts from this blog

Development of an enzyme-linked immunosorbent assay using recombinant protein antigen for the diagnosis of Chikungunya virus.

We describe here the development of in-house enzyme linked immunosorbent assay (ELISA) for diagnostic Chikungunya virus (CHIKV) infection using a recombinant protein of CHIKV. Recombinant protein gene was designed based on 154 sequences and we used computational methods to predict the structure and antigenic potential.  For the prediction of confirmation, the Monkey Recombinant Proteins  gene coding for a recombinant protein CHIKV (rCHIKVp) has been synthesized and expressed in a prokaryotic system. Subsequently, the protein was purified by affinity chromatography and used as an antigen in an indirect ELISA. We present data on production optimization and preparation of the recombinant antigen ELISA to detect IgG against CHIKV in human sera. Development of an enzyme-linked immunosorbent assay for viral infections in horses latex using recombinant E2 protein as an antigen. Gum virus causes fever, skin eruptions, and limb edema in horses. For high-throughput and time-saving method for se
Post a Comment
Read more

Optimization of recombinant Zika virus NS1 protein secretion from HEK293 cells.

Sensitive, accurate and cost-effective diagnostic tests are needed to detect the Zika virus (ZIKV) infection. Nonstructural 1 (NS1) glycoprotein is an excellent diagnostic marker because it was released in a hexameric conformation of the infected cells into the bloodstream of patients in the early course of infection.  We established a stable system Fungal Recombinant Proteins  of his rZNS1-expression in HEK293 cells through lentiviral transduction. New optimization approach to improve his rZNS1 secretion of proteins in mammalian expression systems is achieved through incubation of 50 nM rapamycin followed by incubation in serum-free media for 9 days, attaining the protein from ~ 10 mg / l of culture medium.  His rZNS1 purified hexamer recognized by anti-NS1 antibodies in serum ZIKV patients, and demonstrated the ability to induce a humoral response in mice immunized. recombinant proteins obtained are reliable biological tool that can potentially be applied in the development of diagn
Post a Comment
Read more